Abstract:A prospective study was designed to evaluate the efficacy of azithromycin (AZM) when combined with prednisone therapy compared with prednisone therapy alone in children with primary nephrotic syndrome (PNS) undergoing induction treatment. A prospective randomly controlled clinical trial was conducted. Randomization was performed to select the research subjects who were composed of children with PNS and treated with AZM combined with prednisone (the intervention group) and with prednisone alone (the control group). A total of 211 randomly selected patients with PNS received either AZM combined with prednisone ( n = 106) or prednisone alone ( n = 105) for 6 months. At three months in the follow‐up period, 12 patients were lost to follow up (intervention group, 7; control group, 5), and 6 patients had a transient hypocomplementemia (intervention group, 4 ; control group, 2). AZM was administered at a dose of 10 mg/kg q.d (1 dose per day) for three consecutive days. The median duration before remission was 6 days in the intervention group and 9 days in the control group ( p < 0.0001). Relapse rate differed among the groups at 3 months (11.6 vs. 21.4 %, p = 0.049). No difference in relapse rate was observed between the two groups within 4 to 6 months and at 6 months ( p = 0.168, 0.052). After 4 weeks of treatment, steroid resistance occurred in 1 out of 95 (1.05 %) patients in the intervention group and in 10 out of 98 (10.2 %) patients in the control group ( p = 0.006). After 8 weeks of treatment, no difference was found in steroid resistance between two groups (1/95 vs. 3/98, p = 0.327). During follow-up at 6 months, no difference was exhibited by the two groups on frequent relapse rates ( p = 0.134). Conclusion : If a course of AZM is added to the glucocorticoid-induced treatment among children with PNS, then the sensitivity of prednisone increases. This increase consequently reduces duration to remission and decreases relapse. However, further studies are necessary to confirm these results.

Participation of Clinical Pharmacist in the Therapeutic Protocol of a Case of Pediatric Nephrotic Syndrome

Effectiveness of Pharmacist Dosing Adjustment for Critically Ill Patients Receiving Continuous Renal Replacement Therapy: a Comparative Study.

Effectiveness of Continuous Improvement by a Clinical Pharmacist-Led Guidance Team on the Prophylactic Antibiotics Usage Rationality in Intervention Procedure at a Chinese Tertiary Teaching Hospital

Clinical Pharmacist Interventions on a Chinese Neurology Ward: a 2-Year Service Evaluation

Pharmaceutical care for a child with concurrent cryptococcal meningitis complicated by nephrotic syndrome

Pharmaceutical care in 1 child with nephrotic syndrome with left femoral vein thrombosis

Clinical Pharmacists Involving in Individual Dosage Regimen Design in Respiratory Department

Pharmaceutical care for a child with severe juvenile dermatomyositis

Pharmaceutical Practice of Clinical Pharmacist Participating in the Treatment of 2 Cases of Repeated Use of L-asparaginase Induced Pediatric Asthma

Pharmaceutical services based on therapeutic care pathway for kidney transplantation from donors of infants and young children: a single-center experience

Clinical pharmacists involvement in consultation：analysis and experience of 141 cases of infectious disease

A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome

Case report of clinical pharmacist participating in the treatment of acute pyelonephritis patient with repeated fever

Case report of clinical pharmacists participating in the treatment of Pseudomonas aeruginosa pneumonia with chronic renal failure

Pharmaceutical care for one case of patient with hypertension complicated with the cardiac, lung and renal insufifciency

Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Analysis of Adjustment of Therapeutic Scheme for 1 Elderly Patient with Hypertension by Clinical Pharmacist Using Plasma Protein Binding Rate

Participation of Clinical Pharmacists into the Treatment for Severe Community-acquired Pneumonia Patients with Multiple Organ Dysfunction Syndrome

Case analysis of individualized tacrolimus treatment on patient with nephrotic syndrome

Case report of clinical pharmacist participating in the treatment of urinary tract infection